

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin irritation : Category 2

Eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)
single exposure (Oral)

Specific target organ toxicity - : Category 3
single exposure

Specific target organ toxicity - : Category 2 (Central nervous system)
repeated exposure


Short-term (acute) aquatic : Category 1
hazard

Long-term (chronic) aquatic : Category 1
hazard

GHS label elements in accordance with ABNT NBR 14725 Standard

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

- Hazard pictograms : 
- Signal Word : Danger
- Hazard Statements : H302 + H332 Harmful if swallowed or if inhaled.
 H315 Causes skin irritation.
 H319 Causes serious eye irritation.
 H335 May cause respiratory irritation.
 H360D May damage the unborn child.
 H371 May cause damage to organs (Central nervous system) if swallowed.
 H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.
 H410 Very toxic to aquatic life with long lasting effects.
- Precautionary Statements : **Prevention:**
 P201 Obtain special instructions before use.
 P273 Avoid release to the environment.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- Response:**
 P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
 P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
 P391 Collect spillage.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	Flammable liquids, Category 4 Acute toxicity (Oral), Category 5 Skin irritation, Category 2 Eye irritation, Category 2A Reproductive toxicity, Category 1B Specific target organ toxicity - single exposure, Category 3	>= 20 -< 30

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

Ivermectin	70288-86-7	Acute toxicity (Oral), Category 2 Acute toxicity (Dermal), Category 3 Specific target organ toxicity - single exposure (Oral) (Central nervous system), Category 1 Specific target organ toxicity - repeated exposure (Oral) (Central nervous system), Category 1 Short-term (acute) aquatic hazard, Category 1 Long-term (chronic) aquatic hazard, Category 1	≥ 1 - < 2,5
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	Acute toxicity (Oral), Category 2 Acute toxicity (Inhalation), Category 1 Acute toxicity (Dermal), Category 3 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure (Oral) (Central nervous system), Category 1 Short-term (acute) aquatic hazard, Category 1 Long-term (chronic) aquatic hazard, Category 1	≥ 1 - < 2,5
(dl)-a-Tocopheryl acetate	7695-91-2		< 0,1

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

- | | | |
|---|---|---|
| In case of skin contact | : | Get medical attention.
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person. |
| Most important symptoms and effects, both acute and delayed | : | Harmful if swallowed or if inhaled.
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
May damage the unborn child.
May cause damage to organs if swallowed.
May cause damage to organs through prolonged or repeated exposure. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : | Treat symptomatically and supportively. |
-

SECTION 5. FIRE-FIGHTING MEASURES

- | | | |
|--|---|---|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides
Nitrogen oxides (NO _x) |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment. |
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- | | | |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
|---|---|--|

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapors.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

- Conditions for safe storage : use of administrative controls.
 : Keep in properly labeled containers.
 : Store locked up.
 : Keep tightly closed.
 : Keep in a cool, well-ventilated place.
 : Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 : Strong oxidizing agents
 : Self-reactive substances and mixtures
 : Organic peroxides
 : Explosives
 : Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 µg/100 cm ²	Internal
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m ³ (OEB 3)	Internal
		Wipe limit	150 µg/100 cm ²	Internal
(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 µg/m ³ (OEB 1)	Internal

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of workday	100 mg/l	BR BEI
		5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapor type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	light yellow
Odor	:	characteristic
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 100 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 0,91 - 1,00 mg/l

Solubility(ies)
Water solubility : insoluble

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed or if inhaled.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

Product:

Acute oral toxicity : Acute toxicity estimate: 981,33 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1,84 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:**N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4.150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5.000 mg/kg

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0,023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Acute dermal toxicity : LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2.000 mg/kg

(dl)-a-Tocopheryl acetate:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 3.000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:**N-Methyl-2-pyrrolidone:**

Result : Skin irritation

Ivermectin:

Species : Rabbit
Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : No skin irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

Ivermectin:

Species : Rabbit
Result : Mild eye irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : Mild eye irritation

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

(dl)-a-Tocopheryl acetate:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : negative
Remarks : Based on data from similar materials

Ivermectin:

Routes of exposure : Dermal
Species : Humans
Result : Does not cause skin sensitization.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximization Test
Routes of exposure : Skin contact
Result : Not a skin sensitizer.

(dl)-a-Tocopheryl acetate:

Test Type : Draize Test
Routes of exposure : Skin contact
Species : Humans
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
 Result: negative
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Method: OECD Test Guideline 474
 Result: negative
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
 Species: Hamster
 Application Route: Ingestion
 Method: OECD Test Guideline 475
 Result: negative
- Ivermectin:**
- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
 Test system: human diploid fibroblasts
 Result: negative
- Test Type: Mouse Lymphoma
 Result: negative
- abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
- Test Type: In vitro mammalian cell gene mutation test
 Test system: Chinese hamster lung cells
 Result: negative
- Test Type: Alkaline elution assay
 Result: negative
- Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
 Species: Mouse
 Application Route: Intraperitoneal injection
 Result: negative
- (dl)-a-Tocopheryl acetate:**
- Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : inhalation (vapor)
Exposure time : 2 Years
Result : negative

Ivermectin:

Species : Rat
Application Route : Oral
NOAEL : 1,5 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

Species : Mouse
Application Route : Oral
NOAEL : 2,0 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

(dl)-a-Tocopheryl acetate:

Species : Rat

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

Application Route : Ingestion
 Exposure time : 104 weeks
 Result : negative

Reproductive toxicity

May damage the unborn child.

Components:**N-Methyl-2-pyrrolidone:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 416
 Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 414
 Result: positive

Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: inhalation (vapor)
 Result: positive

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Ingestion
 Result: positive

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Ivermectin:

Effects on fertility : Test Type: Fertility
 Species: Rat
 Application Route: Oral
 Fertility: NOAEL: 0,6 mg/kg body weight
 Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development
 Species: Mouse
 Application Route: Oral
 Developmental Toxicity: NOAEL: 0,2 mg/kg body weight
 Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 0,4 mg/kg body weight

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

Result: Embryotoxic effects and adverse effects on the offspring were detected.
 Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
 Species: Rabbit
 Application Route: Oral
 Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility
 Species: Rat, male
 Application Route: Oral
 Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
 Species: Rat
 Application Route: Oral
 Early Embryonic Development: NOAEL: 0,12 mg/kg body weight
 Result: Fetotoxicity.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Mouse
 Application Route: Oral
 General Toxicity Maternal: NOAEL: 0,05 mg/kg body weight
 Developmental Toxicity: NOAEL: 0,2 mg/kg body weight
 Result: Cleft palate
 Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: LOAEL: 2 mg/kg body weight
 Result: Cleft palate, Teratogenic effects., Reduced embryonic survival
 Remarks: Adverse developmental effects were observed

Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 1,6 mg/kg body weight
 Result: Teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

(dl)-a-Tocopheryl acetate:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

test
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Ingestion
 Result: negative

STOT-single exposure

May cause respiratory irritation.
 May cause damage to organs (Central nervous system) if swallowed.

Components:**N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

Ivermectin:

Target Organs : Central nervous system
 Assessment : Causes damage to organs.

STOT-repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:**Ivermectin:**

Target Organs : Central nervous system
 Assessment : Causes damage to organs through prolonged or repeated exposure.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Routes of exposure : Ingestion
 Target Organs : Central nervous system
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****N-Methyl-2-pyrrolidone:**

Species : Rat, male
 NOAEL : 169 mg/kg
 LOAEL : 433 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Method : OECD Test Guideline 408

Species : Rat
 NOAEL : 0,5 mg/l

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

LOAEL : 1 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 96 Days
 Method : OECD Test Guideline 413

Species : Rabbit
 NOAEL : 826 mg/kg
 LOAEL : 1.653 mg/kg
 Application Route : Skin contact
 Exposure time : 20 Days

Ivermectin:

Species : Dog
 NOAEL : 0,5 mg/kg
 LOAEL : 1 mg/kg
 Application Route : Oral
 Exposure time : 14 Weeks
 Target Organs : Central nervous system
 Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
 NOAEL : 1,2 mg/kg
 Application Route : Oral
 Exposure time : 2 Weeks
 Remarks : No significant adverse effects were reported

Species : Rat
 NOAEL : 0,4 mg/kg
 LOAEL : 0,8 mg/kg
 Application Route : Oral
 Exposure time : 3 Months
 Target Organs : spleen, Bone marrow, Kidney

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
 NOAEL : 1,5 mg/kg
 Application Route : Oral
 Exposure time : 24 Months
 Target Organs : Central nervous system
 Symptoms : Tremors, ataxia

Species : Mouse
 NOAEL : 4,0 mg/kg
 Application Route : Oral
 Exposure time : 24 Months
 Target Organs : Central nervous system
 Symptoms : Tremors, ataxia

Species : Dog
 NOAEL : 0,25 mg/kg
 LOAEL : 0,5 mg/kg
 Application Route : Oral
 Exposure time : 53 Weeks
 Target Organs : Central nervous system

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

Symptoms : Tremors, weight loss
 Remarks : mortality observed

Species : Monkey
 NOAEL : 1,0 mg/kg
 Application Route : Oral
 Exposure time : 14 Weeks
 Target Organs : Central nervous system

(dl)-a-Tocopheryl acetate:

Species : Rat
 NOAEL : 500 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.
 Eye contact : Remarks: May irritate eyes.
 Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1.000 mg/l
 Exposure time: 24 h
 Method: DIN 38412

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600,5 mg/l
 Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92,6 mg/l
 Exposure time: 72 h

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12,5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 600 mg/l
Exposure time: 30 min
Method: ISO 8192

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10.000

M-Factor (Chronic aquatic toxicity) : 10.000

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3,2 µg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9,6 µg/l
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0,022 µg/l
Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0,34 µg/l
Exposure time: 48 h

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
 Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 10.000

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,52 µg/l
 Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,03 µg/l
 Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0,0035 µg/l
 Exposure time: 28 d

M-Factor (Chronic aquatic toxicity) : 10.000

Toxicity to microorganisms : EC50: > 1.000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition

(dl)-a-Tocopheryl acetate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l
 Exposure time: 28 d

Toxicity to microorganisms : EC50: > 927 mg/l
 Exposure time: 30 min
 Method: ISO 8192

Persistence and degradability**Components:****N-Methyl-2-pyrrolidone:**

Biodegradability : Result: Readily biodegradable.

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Ivermectin:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

(dl)-a-Tocopheryl acetate:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 21,7 - 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Bioaccumulative potential**Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n- : log Pow: -0,46
octanol/water Method: OECD Test Guideline 107

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n- : log Pow: 3,22
octanol/water

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n- : log Pow: 4
octanol/water

Mobility in soil**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environ- : log Koc: > 3,6
mental compartments

Other adverse effects

No data available

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

Ivermectin / Abamectin Liquid Formulation

Version 6.14 Revision Date: 30.09.2023 SDS Number: 1210001-00024 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class : 9
Packing group : III
Labels : 9
Hazard Identification Number : 90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)
BR BEI : Brazil. NR7. Parameters for Biological Control of Occupational Exposure to Some Chemical Agents

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.14	30.09.2023	1210001-00024	Date of first issue: 10.01.2017

Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8